The Experimental Therapeutics (ET) research program is one of OSUCCC–James' six highly interactive cancer Research Programs. The programs comprise more than 50 members within Ohio State and affiliated colleges.
The ET is devoted to scientific excellence in cancer and is specifically tailored to take advantage of its members’ professional strengths and expertise. The program comprises a diverse group of experts encompassing 16 departments within the OSU College of Medicine and Pharmacy, including numerous physician scientists (MDs), MD/PhDs and PhDs.
The ET’s primary goal is to discover and develop effective new cancer treatments by lowering the cancer cell’s threshold for apoptosis, thus promoting biological destruction of cancer. The program focuses on:
- Identifying novel molecules with a unique action mechanism that demonstrates promise in cancer therapy
- Therapeutically applying epigenetic modification to enhance cancer treatment while avoiding excessive toxicity
- Collaborating with immunologists to develop combined therapeutic strategies for effective cancer treatment
Multi-disciplinary teams of scientists are dedicated to translational science, identifying therapeutic agents that are more effective and less toxic and bringing therapy from basic science laboratories to the clinic.
In addition to the ET’s therapeutic research, program leaders collaborate with numerous other OSUCCC–James scientific programs that pertain to both solid and liquid tumors.
Academic Departments Represented: 16
Nationwide Children's Hospital
Arts and Sciences
Leaders: Michael Grever, MD; Samson T. Jacob, PhD